Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk.

Document type:: Journal Article; Research Support, Non-U.S. Gov't
Author(s):: Weingold, Robert; Zinman, Bernard; Mattheus, Michaela; Ofstad, Anne Pernille; Steubl, Dominik; Wanner, Christoph; Inzucchi, Silvio E
Title:: Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk.
Abstract:: T2D is a well-established risk factor for development and progression of CKD. KDIGO recommends categorization of risk by likelihood of progression to ESKD. Compared to placebo, empagliflozin decreases likelihood of worsening (OR 0.70, 95 % CI 0.62-0.78) and increases likelihood of improvement (OR 1.56, 95 % CI 1.30-1.86) in KDIGO risk category.
Journal title abbreviation:: J Diabetes Complications
Year:: 2023
Journal volume:: 37
Journal issue:: 11
Fulltext / DOI:: doi:10.1016/j.jdiacomp.2023.108628
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/37852075
Print-ISSN:: 1056-8727
TUM Institution:: Professur für Nephrologie (Prof. Heemann)
BibTeX

Occurrences: